Icade

ENXTPA:ICAD 주식 리포트

시가총액: €1.6b

Icade 향후 성장

Future 기준 점검 3/6

Icade (는) 각각 연간 86.7% 및 1.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 94.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.6% 로 예상됩니다.

핵심 정보

86.7%

이익 성장률

94.65%

EPS 성장률

REITs 이익 성장11.8%
매출 성장률1.2%
향후 자기자본이익률5.62%
애널리스트 커버리지

Good

마지막 업데이트05 Jun 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • Jun 06

ICAD: Limited Downside View Will Still Pressure Shares Going Forward

Analysts have raised their fair value estimate for Icade from €16.30 to €17.00, citing a higher Street price target of €22 and the view that downside risk at current levels now appears more limited. What's in the News Icade has scheduled a Special and Extraordinary Shareholders Meeting for June 10, 2026, at the Coeur Defense building, Tour B Espace Comet, 24th floor, 100 Esplanade du General de Gaulle, Paris La Defense Cedex, France.
내러티브 업데이트 • May 22

ICAD: Slower Healthcare Exit And Paused Special Payouts Will Shape Balanced Outlook

Analysts have nudged their fair value estimate for Icade slightly lower to about €21.31. This reflects a reduced price target and updated assumptions around slower revenue growth, a modestly softer profit margin, a higher discount rate and the view that asset disposals and potential special dividends may take longer to materialise.
내러티브 업데이트 • May 06

ICAD: Slower Healthcare Disposal And Halted Special Payouts Will Pressure Shares

Analysts have reduced their price target on Icade from €30 to €25, citing expectations that the healthcare business disposal could take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts are flagging a more cautious stance on Icade, with recent research pointing to timing and payout uncertainties that weigh on sentiment.
내러티브 업데이트 • Apr 21

ICAD: Slower Healthcare Disposal And Lost Special Dividends Will Pressure Shares

Analysts have trimmed their price target for Icade to €25 from €30, reflecting expectations that the planned disposal of the healthcare business may take longer and that special dividends are no longer assumed over the next three years. Analyst Commentary Bearish analysts have shifted to a more cautious stance on Icade, with the rating cut to Equal Weight from Overweight and the price target moved to €25 from €30.
내러티브 업데이트 • Apr 06

ICAD: Slower Healthcare Disposal And Missing Special Dividends Will Shape Fair Outlook

Narrative Update The analyst price target for Icade has been trimmed to €21.35 from €21.54. This reflects a more cautious stance from analysts after recent downgrades and expectations that healthcare asset disposals and potential special dividends may take longer to play out.
내러티브 업데이트 • Mar 23

ICAD: Slower Healthcare Exit And Reset Distributions Will Support Future Repricing

Analysts have trimmed their fair value estimate for Icade to about €29.91 from €31.29, echoing recent price target cuts, such as the move from €30 to €25, as they factor in a longer timeline for healthcare asset disposals and the absence of expected special dividends. Analyst Commentary The recent research updates on Icade point to a more cautious stance as analysts reassess how quickly the group can execute on its healthcare disposals and how generous future shareholder returns might be.
내러티브 업데이트 • Mar 08

ICAD: Slower Healthcare Disposals And Lost Special Dividends Will Shape Fairly Valued Outlook

Analysts have modestly trimmed their fair value estimate for Icade from €22.03 to about €21.54. This reflects updated views on slower progress on healthcare disposals, a higher required discount rate and the removal of assumed special dividends after recent downgrades and price target cuts on the stock.
내러티브 업데이트 • Feb 22

ICAD: Higher Office Risk Premium Will Set Stage For Future Repricing

Analysts have reduced their fair value estimate for Icade from about €36.67 to about €31.29, reflecting a higher assumed discount rate and lower profit margin expectations following recent rating cuts and a lower €18 Street price target. Analyst Commentary Recent rating actions on Icade have leaned cautious, with cuts to both recommendations and price targets that feed into the lower fair value estimate.
내러티브 업데이트 • Feb 08

ICAD: Office Risk Repricing And Downgrades Will Shape Fairly Valued Outlook

Analysts have trimmed their fair value estimate for Icade from €23.33 to €22.03. This reflects a slightly higher discount rate, a modestly lower profit margin outlook and recent downgrades that cite a higher perceived equity risk premium in offices.
내러티브 업데이트 • Jan 24

ICAD: Office Risk Repricing And Downgrades Will Shape Future Share Performance

Analysts have trimmed their fair value estimate for Icade from about €23.46 to roughly €23.33, citing slightly higher required returns, more cautious assumptions on revenue growth and profit margins, and recent Street downgrades, including a cut in one price target from €25 to €18. Analyst Commentary Bullish Takeaways Bullish analysts may see the recent pullback in fair value and price targets as already reflecting higher equity risk premiums in offices, which can limit further downside if execution on existing projects is steady.
내러티브 업데이트 • Jan 10

ICAD: Office Downgrades And Higher Risk Premium Will Pressure Shares

Analysts have trimmed their price expectations for Icade to around €14.60, reflecting recent rating downgrades and a higher equity risk premium for office assets. This has been incorporated into updated assumptions for revenue growth, profit margins and future P/E levels.
내러티브 업데이트 • Dec 26

ICAD: Office Risk Repricing Will Shape Margins And Share Performance

Analysts have lowered their price target on Icade from EUR 25 to EUR 18. This reflects a higher perceived equity risk in offices, alongside slightly faster expected revenue growth but weaker profit margins and a higher valuation multiple.
내러티브 업데이트 • Dec 12

ICAD: Office Weakness And Higher Equity Risk Will Pressure Shares

Analysts have cut their price target on Icade from EUR 17.80 to EUR 14.60, reflecting a lower revenue growth outlook and higher perceived equity risk in offices, even as profit margins are expected to improve. Analyst Commentary Bearish analysts have recently shifted their stance on Icade, highlighting a weaker outlook for office assets and increasing caution around the company’s equity risk profile.
User avatar
새로운 내러티브 • Apr 28

Pulse Building Lease With Seine-Saint-Denis Will Boost Portfolio Strength

Improved rental growth expected from the lease agreement and focus on prime locations may enhance revenue stability.
분석 기사 • Feb 23

A Look At Icade's (EPA:ICAD) Share Price Returns

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you...
분석 기사 • Jan 19

How Did Icade SA's (EPA:ICAD) 8.0% ROE Fare Against The Industry?

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
분석 기사 • Dec 13

What Type Of Shareholders Make Up Icade SA's (EPA:ICAD) Share Registry?

If you want to know who really controls Icade SA ( EPA:ICAD ), then you'll have to look at the makeup of its share...

이익 및 매출 성장 예측

ENXTPA:ICAD - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20281,3812441111815
12/31/20271,3271548312085
12/31/20261,302479622535
12/31/20251,337-123300300N/A
9/30/20251,338-155314314N/A
6/30/20251,339-187328328N/A
3/31/20251,376-231347347N/A
12/31/20241,412-275366366N/A
9/30/20241,468-614316316N/A
6/30/20241,523-953265265N/A
3/31/20241,524-1,121251251N/A
12/31/20231,525-1,289238238N/A
9/30/20231,494-1,116317317N/A
6/30/20231,464-944397397N/A
3/31/20231,467-657319319N/A
12/31/20221,469-370242242N/A
9/30/20221,496-61N/AN/AN/A
6/30/20221,524249547224N/A
3/31/20221,586324538377N/A
12/31/20211,648399529529N/A
6/30/20211,640280-51600N/A
3/31/20211,53417834625N/A
12/31/20201,42976120650N/A
6/30/20201,458259-233453N/A
3/31/20201,485278-325411N/A
12/31/20191,512298-417369N/A
9/30/20191,587235N/A358N/A
6/30/20191,662173N/A346N/A
3/31/20191,717165N/A351N/A
12/31/20181,773156N/A356N/A
9/30/20181,714137N/A372N/A
6/30/20181,655118N/A387N/A
3/31/20181,642142N/A362N/A
12/31/20171,629165N/A337N/A
6/30/20171,596106N/A255N/A
3/31/20171,54275N/A235N/A
12/31/20161,48745N/A215N/A
6/30/20161,391-101N/A309N/A
3/31/20161,411-144N/A307N/A
12/31/20151,431-187N/A305N/A
6/30/20151,64982N/A526N/A

애널리스트 향후 성장 전망

수입 대 저축률: ICAD 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ICAD (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ICAD 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ICAD 의 수익(연간 1.2%)이 French 시장(연간 5.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: ICAD 의 수익(연간 1.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ICAD의 자본 수익률은 3년 후 5.6%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/10 18:49
종가2026/06/10 00:00
수익2025/12/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Icade는 18명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Celine HuynhBarclays
Paul MayBarclays
Aaron GuyBarclays